OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Farid on Current and Future Investigations of MDC-CAR-BCMA001 in Myeloma and AL Amyloidosis

April 22nd 2025

Kiavasch Mohammad Nejad Farid, MD, discusses 2 planned investigations of MDC-CAR-BCMA001 in relapsed/refractory multiple myeloma and AL amyloidosis.

Dr Cho on the Investigation of Niraparib/Bevacizumab in Platinum-Sensitive, Recurrent Ovarian Cancer

April 22nd 2025

Hyun Woong Cho, MD, PhD, explains the rationale for assessing niraparib/bevacizumab in platinum-sensitive, recurrent ovarian cancer.

Dr Tykodi on Long-Term Outcomes for Nivolumab Plus Ipilimumab in Favorable-Risk Advanced RCC

April 22nd 2025

Scott Tykodi, MD, PhD, discusses data from CheckMate 214 for nivolumab plus ipilimumab vs sunitinib in favorable-risk advanced RCC.

Dr Tarantino on Trials Reshaping the Perioperative Treatment Algorithm for HER2+ Breast Cancer

April 22nd 2025

Paolo Tarantino, MD, the clinical impact of the KATHERINE trial in reshaping the post-surgical treatment algorithm for HER2+ breast cancer care.

Dr Garfall on the Rationale of the Phase 2 BMT CTN 1902 Trial in Myeloma

April 21st 2025

Alfred L. Garfall, MD, MS, discusses the rationale of the phase 2 BMT CTN 1902 trial in multiple myeloma.

Dr Rampal on the Benefits and Limitations of JAK Inhibitors in Myelofibrosis

April 21st 2025

Raajit Rampal, MD, discusses treatment decision-making factors, such as JAK inhibitor efficacy and signs of treatment failure, for myelofibrosis.

Dr Flora on the Implications of Emerging AI Models for Oncology Care

April 21st 2025

Douglas B. Flora, MD, LSSBB, discusses the potential utility of GPT models for improving clinical trial screening and workflows in oncology.

Dr Ip on Reasons for Studying Real-World CAR T-Cell Therapy Outcomes in LBCL

April 21st 2025

Andrew Ip, MD, discusses the need for real-world studies investigating the efficacy and safety of CAR T-cell therapy in patients with LBCL.

Dr Bishop on the Rationale for Evaluating Anito-Cel in R/R Myeloma

April 21st 2025

Michael R. Bishop, MD, explains the rationale for assessing the CAR T-cell therapy anito-cel in relapsed/refractory multiple myeloma.

Dr Shadman on the Framework of a Meta Analysis of BTK Inhibitors in R/R CLL

April 21st 2025

Mazyar Shadman, MD, MPH, discusses the rationale and methodological framework of a network meta-analysis aimed at evaluating the comparative efficacy of BTK inhibitors in R/R CLL.

Dr Bowman on Risk Factors for Kidney Cancer Development

April 21st 2025

I. Alex Bowman, MD, discusses recommended strategies for kidney cancer risk reduction.

Dr Choi on the Importance of Education on CAR T-Cell Therapy Manufacturing in Hematologic Malignancies

April 21st 2025

Yeong “Christopher” Choi, PhD, MBA, discusses importance of product and process education to mitigate variability in CAR T-cell therapy manufacturing in hematologic malignancies.

Dr Agustí on Patient Eligibility for Evaluating Chemoradiotherapy vs Radiotherapy Alone in Intermediate-Risk Cervical Cancer

April 21st 2025

Núria Agustí, MD, discusses patient eligibility in a cohort study assessing adjuvant chemoradiotherapy vs radiotherapy alone in patients with cervical cancer.

Dr Kaklamani on the Efficacy of Inavolisib in HR+, PIK3CA-Mutated Breast Cancer

April 18th 2025

Virginia Kaklamani, MD, DSc, discusses inavolisib's efficacy in PIK3CA-mutated metastatic breast cancer, as well as the importance of biomarker testing.

Dr Zonder on the Importance of Early Screening for Myeloma Among High-Risk Patients

April 18th 2025

Jeffrey Zonder, MD, discusses the need for increased screening for patients who are at higher risk of developing multiple myeloma.

Dr Hernandez-Ilizaliturri on Studying Immunologic Changes With Venetoclax in CLL

April 18th 2025

Francisco J. Hernandez-Ilizaliturri, MD, discusses the rationale behind assessing immunologic changes seen with venetoclax treatment in patients with CLL.

Dr Jhaveri on the Evolving Role of Inavolisib in PIK3CA-Mutated Metastatic Breast Cancer

April 18th 2025

Komal Jhaveri, MD, FACP, discusses the success of the INAVO120 trial of inavolisib/palbociclib/fulvestrant in PIK3CA-mutated metastatic breast cancer.

Dr Alencar on the Ongoing Development of NX-5948 in CLL and B-Cell Malignancies

April 18th 2025

Alvaro Alencar, MD, discusses research needed to clarify the optimal dosing, role, and sequencing of NX-5948 in CLL and other B-cell malignancies.

Dr Matrana on Factors Influencing Upfront Treatment Approaches for RCC

April 18th 2025

Marc R. Matrana, MD, shares his approach to navigating treatment selection when initiating therapy for patients with RCC.

Dr McLornan on the Challenges of Identifying Optimal Timing for Transplantation in Myelofibrosis

April 18th 2025

Donal McLornan, MBBCh, MRCP, PhD, FRCPath, explains the challenges of choosing optimal timing for allogeneic hematopoietic cell transplantation in myelofibrosis.